Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Muntlig 'pustetest' for å måle anabole sensitivitet hos unge og eldre voksne på forskjellige aktivitetsnivåer (ARBT)

16. november 2026 oppdatert av: Daniel Moore, University of Toronto

Effekten av en ikke-invasiv 13CO2 'pustetest' for å oppdage anabolsk motstand etter trinnreduksjon hos yngre og eldre voksne

Recent work in the investigators laboratory has examined the ability of a non-invasive 13CO2 breath-test to assess differences in amino acid oxidation rates and net balance in young healthy males following protein feeding and resistance exercise. The investigators aim to test the efficacy of this non-invasive 13CO2 breath-test to assess for differences in anabolic sensitivity between young and older adults following an acute period of habitual and reduced physical activity.

Studieoversikt

Detaljert beskrivelse

Aging is associated with a phenomenon known as anabolic resistance, whereby individuals are less responsive to anabolic stimuli (i.e., resistance exercise, dietary protein ingestion). Mild and severe reductions in physical activity are also known to play a key role in the emergence of anabolic resistance. Therefore, the purpose of this study is to investigate the ability of a non-invasive 13CO2 breath-test to assess differences in whole-body leucine oxidation and leucine net balance between younger and older individuals under conditions of habitual activity and following a period of reduced activity/step-reduction. In this manner, the ability of the methodology to distinguish anabolic sensitivity between young and older adult populations will be assessed.

Methods:

Total participant time commitment will span over 4 sessional dates:

Session 1 - Introduction Interested participants will be recruited to engage in a video conference call to undergo an introductory session. Participants will be provided with a comprehensive introduction to the study which will explain the research objectives, conduct, and associated risks. Participants will provide informed consent prior to the collection of any study information (i.e., anthropometrics and habitual activity levels). Eligibility will also be screened for at this time.

Session 2 - Body Composition Assessment Participants will consume a bolus of deuterium oxide (D2O) and provide saliva samples in order to estimate fat-free mass.

The remainder of the study will consist of seven consecutive days, wherein Phase 1 (Habitual Activity) will be subsequently followed by Phase 2 (Step-Reduction).

Phase 1 - Habitual Activity (Days 1-3) Participants will be asked to engage in their habitual activity pattern (> 7000 steps/day) while wearing an accelerometer and pedometer. Participants will be further instructed to maintain their normal dietary patterns and to track their diets over the course of these three days using diet logs.

Session 3 - Habitual Activity Metabolic Trial (Day 4) On the morning of the fourth day, following three days of habitual activity, participants will be subjected to the non-invasive 13CO2 breath-test to assess for whole-body leucine oxidation and net balance. This date will also serve as a lead-in to the subsequent Phase 2.

Phase 2 - Step-Reduction (Days 4-6) Participants will be asked to maintain their normal dietary patterns and track their dietary intake, but will need to adhere to a reduced daily step count (<2000 steps/day). Accelerometers and pedometers will be worn again during this period.

Session 4 - Step-Reduction Metabolic Trial (Day 7) On the morning of the 7th day, following three days of reduced daily step-count, participants will be subjected again to the non-invasive 13CO2 breath-test to assess for whole-body leucine oxidation and net balance. Ultimately, this will allow us to determine whether 3-days of reduced step-count will impart any changes on anabolic sensitivity.

For each metabolic trial, two urine samples (baseline and pooled enriched) will be collected, in addition to breath samples collected over a 6-hour post-prandial period at 20-30 minute intervals. These biological samples will be used to measure tracer excretion and oxidation, allowing us to determine rates of protein metabolism.

Studietype

Intervensjonell

Registrering (Faktiske)

32

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5S2C9
        • Goldring Centre for High Performance Sport at the University of Toronto

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Healthy young (age: 18-35 years) or older (age: 60-80 years) adults
  • Average daily step-count >7,000/day
  • BMI between normal to overweight (18.5-29.9 kg/m2)

Exclusion Criteria:

  • Regular use of nonsteroidal anti-inflammatory drugs (with the exception of daily low-dose aspirin)
  • Use of anticoagulants
  • Use of a walker, cane, or assistive walking device
  • Current or recently remised cancer
  • Infectious or gastrointestinal disease
  • Inability to comply with study protocol (e.g., >2,000 steps/day during Step-Reduction Phase)
  • Regular tobacco use
  • Self-reported illicit drug use (e.g. growth hormone, testosterone, etc.)
  • Diagnosed chronic illness (e.g. type 2 diabetes, heart disease, thyroid disease)
  • Pregnant
  • Hormonal Replacement Therapy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Young Adults

Equal sex distribution (10M/10F); ages 18-35 years old.

Participants will be required to reduce their daily step-counts to <2,000 steps/day. Further, they will be required to refrain from structured physical activity.

Andre navn:
  • Redusert fysisk aktivitet

Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain >7,000 steps/day.

Andre navn:
  • Frilivsaktivitet
Aktiv komparator: Older Adults

Equal sex distribution (6M/6F); ages 60-80 years old.

Participants will be required to reduce their daily step-counts to <2,000 steps/day. Further, they will be required to refrain from structured physical activity.

Andre navn:
  • Redusert fysisk aktivitet

Participants will maintain habitual levels of physical activity (inclusive of structured physical activity). Participants will be required to maintain >7,000 steps/day.

Andre navn:
  • Frilivsaktivitet

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Exogenous Leucine Oxidation (umol/kg)
Tidsramme: 6 hours

Exogenous Leucine Oxidation determined from breath 13CCO2 enrichment. Breath samples will be collected every 20-30min after test drink ingestion to determine breath 13CO2 enrichment. Total leucine oxidation will be determined from the area under the 13CO2 enrichment by time curve.

6 hours
Net Leucine Retention (umol/kg)
Tidsramme: 6 hours

Whole-Body Net Leucine Retention determined from the difference between exogenous leucine oxidation and leucine ingestion the 6 hour measurement period.

6 hours

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Daniel Moore, PhD, University of Toronto
  • Studieleder: Hugo JW Fung, PhD (c), University of Toronto

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. februar 2022

Primær fullføring (Faktiske)

31. mars 2024

Studiet fullført (Faktiske)

31. mars 2024

Datoer for studieregistrering

Først innsendt

7. november 2021

Først innsendt som oppfylte QC-kriteriene

18. januar 2022

Først lagt ut (Faktiske)

1. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2023

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere